Home Healthcare Biotechnology Biosimilars Market

Biosimilars Market Size, Share & Trends Analysis Report By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factors, Erythropoiesis-Stimulating Agents, Insulin Analogs, Others), By Indication (Oncology, Autoimmune & Inflammatory Diseases, Diabetes, Blood Disorders, Ophthalmology, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 31, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Biosimilars Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Monoclonal Antibodies
    2. Granulocyte Colony-Stimulating Factors
    3. Erythropoiesis-Stimulating Agents
    4. Insulin Analogs
    5. Others
  2. Biosimilars Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Autoimmune & Inflammatory Diseases
    3. Diabetes
    4. Blood Disorders
    5. Ophthalmology
    6. Others
  3. Biosimilars Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores and Retail Pharmacies
    3. Online Pharmacies
  4. Regional Biosimilars Market
    1. North America
      1. North America Biosimilars Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
      2. North America Biosimilars Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune & Inflammatory Diseases
        3. Diabetes
        4. Blood Disorders
        5. Ophthalmology
        6. Others
      3. North America Biosimilars Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      5. Canada
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
    2. Europe
      1. Europe Biosimilars Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
      2. Europe Biosimilars Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune & Inflammatory Diseases
        3. Diabetes
        4. Blood Disorders
        5. Ophthalmology
        6. Others
      3. Europe Biosimilars Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      5. Germany
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      6. France
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      7. Spain
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      8. Italy
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      9. Russia
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      10. Nordic
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      11. Benelux
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      12. Rest of Europe
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
    3. APAC
      1. APAC Biosimilars Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
      2. APAC Biosimilars Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune & Inflammatory Diseases
        3. Diabetes
        4. Blood Disorders
        5. Ophthalmology
        6. Others
      3. APAC Biosimilars Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      5. Korea
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      6. Japan
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      7. India
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      8. Australia
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      9. Taiwan
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      10. South East Asia
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      11. Rest of Asia-Pacific
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Biosimilars Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
      2. Middle East and Africa Biosimilars Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune & Inflammatory Diseases
        3. Diabetes
        4. Blood Disorders
        5. Ophthalmology
        6. Others
      3. Middle East and Africa Biosimilars Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      5. Turkey
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      6. Saudi Arabia
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      7. South Africa
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      8. Egypt
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      9. Nigeria
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      10. The rest of MEA
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
    5. LATAM
      1. LATAM Biosimilars Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
      2. LATAM Biosimilars Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune & Inflammatory Diseases
        3. Diabetes
        4. Blood Disorders
        5. Ophthalmology
        6. Others
      3. LATAM Biosimilars Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      5. Mexico
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      6. Argentina
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      7. Chile
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      8. Colombia
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
      9. Rest of LATAM
        1. Monoclonal Antibodies
        2. Granulocyte Colony-Stimulating Factors
        3. Erythropoiesis-Stimulating Agents
        4. Insulin Analogs
        5. Others
        6. Oncology
        7. Autoimmune & Inflammatory Diseases
        8. Diabetes
        9. Blood Disorders
        10. Ophthalmology
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores and Retail Pharmacies
        14. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.